Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal bevacizumab for malignant ascites in chemotherapy-resistant gynecologic cancers
ACTRN12611000801910Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by University of Sydney. Primary endpoint: Primary efficacy: time from first to second therapeutic ascitic drainage. Started Dec 2013; status: completed.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ACTRN12611000801910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000801910.